LOGO
LOGO

Quick Facts

Amer Sports Q1 Profit Rises, Lifts FY26 Outlook; Stock Up In Pre-Market

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News   | Join Us

Amer Sports, Inc. (AS), on Tuesday reported higher profit for the first quarter as revenue rose.

In pre-market activity on NYSE, shares of Amer Sports were up 3.26 percent, changing hands at $34.25, after closing Monday's regular session 0.94 percent higher.

For the first quarter, Net earnings rose 22 percent to $164.6 million or $0.29 per share from $134.6 million or $0.24 per share last year.

On an adjusted basis, Net earnings advanced to $218.0 million or $0.38 per share from $148.1 million or $0.27 per share a year earlier.

Adjusted EBITDA was $432.4 million compared to $299.4 million a year before.

Quarterly revenue increased 32 percent to $1,945.5 million from $1,472.5 million in the previous year.

Looking ahead to the second quarter, revenue growth percentage is expected to be between 22 and 24 percent. Fully diluted EPS is anticipated between $0.08 - 0.10.

Further, for fiscal 2026, the company raised its guidance, with revenue growth percentage of which is forecasted between 20 — 22 percent compared to 16 - 18 percent last year. Fully diluted EPS is expected between $1.18 - 1.23 compared to $1.10 - 1.15 a year earlier.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update: May 11 – May 15, 2026

May 15, 2026 15:25 ET
Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.

RELATED NEWS
Latest Updates on COVID-19